Remepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson’s disease, bringing the company’s total capital raised to $62 million. The round was led by O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany.
Existing and new investors participating in the financing included NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital and IT-Farm Corp.
Remepy plans to use the capital to expand its pharmaceutical co-development partnerships, grow its Hybrid Drug platform and pipeline, and support global Phase III development of Hybridopa.
The Phase III program is expected to begin in the fourth quarter of 2026.
Remepy describes Hybrid Drugs as a new treatment category combining prescription medicines with personalized, AI-driven therapeutic applications.
The company’s approach integrates pharmacological treatment with adaptive physical, cognitive and behavioral interventions delivered through software.
Remepy is seeking to make those combined interventions available through a conventional prescription model.
The platform is also designed as a development tool for pharmaceutical companies, potentially allowing drugmakers to create additional intellectual property, support lifecycle management and differentiate therapies through accompanying personalized software.
Remepy recently established a strategic collaboration with Merck KGaA, Darmstadt, Germany, to develop Hybrid Drugs across multiple indications, beginning with rare tumors.
Hybridopa is Remepy’s lead internal program.
The investigational Parkinson’s treatment combines pharmacological therapy with Remepy’s software-driven therapeutic approach.
Remepy said Phase IIa testing produced encouraging results involving both motor and non-motor Parkinson’s symptoms.
The company is now preparing for a global Phase III program expected to begin in Q4 2026.
Hybridopa remains investigational and has not been approved by the FDA.
Remepy believes emerging regulatory frameworks covering drug-software combination products could support broader development of its Hybrid Drug approach.
The company’s longer-term strategy involves partnering with pharmaceutical companies across multiple disease areas while continuing to develop proprietary programs.
KEY QUOTES:
“We believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient. Over the past year, we’ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment, and partnerships with leading pharmaceutical companies. This financing allows us to advance Phase III of Hybridopa for Parkinson’s disease, and expand the Hybrid Drug model across multiple therapeutic areas.”
Michal Tsur, PhD, And Or Shoval, Co-CEOs Of Remepy
“We’re excited to lead Remepy’s Series A and support an exceptional team pioneering a new category of medicine. By bringing together biotechnology, AI, and digital health, Remepy is redefining how medicines are developed and delivered. With compelling clinical data, growing regulatory momentum, and strong validation from leading pharmaceutical partners, we believe Hybrid Drugs have the potential to transform patient care, and we’re proud to support Remepy in its next phase of growth.”
Ziv Kop, Managing Partner At O.G. Venture Partners Israel
“Remepy’s pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines. Our investment from M Ventures is intended to further enable the company, underscoring our belief that this new class of medicine, that combines innovative therapeutics with AI-driven, patient-centered care, has the potential to redefine medicine. We look forward to advancing it across multiple drug classes and disease areas.”
Dr. Eyal Ben Ami, Scientific Lead At M Ventures
“We’ve believed in Remepy’s vision since day one. The team’s ability to translate bold ideas into clinical and commercial momentum has only strengthened our conviction, and we’re excited to continue supporting the company as it enters its next stage of growth.”
Gigi Levi-Weiss, Founding Partner At NFX
